Southern Palladium Ltd Stock Price Today (NSE: SDL)
Fundamental Score
Southern Palladium Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Southern Palladium Ltd share price today is ₹34.93, up +0.00% on NSE/BSE as of 30 March 2026. Southern Palladium Ltd (SDL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹17.43 (Cr). The 52-week high for SDL share price is ₹35.18 and the 52-week low is ₹19.01.
Southern Palladium Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Southern Palladium Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Southern Palladium Share Price: A Financial Analysis
The pharmaceutical sector, characterized by stringent regulatory hurdles and extensive research & development cycles, often rewards companies with strong patent portfolios and efficient operational management. Today's analysis focuses on the Southern Palladium share price, currently trading at ₹31.69. This valuation needs careful consideration alongside its financial performance indicators.
One of the most pressing concerns is the company's Return on Capital Employed (ROCE) which stands at a stark -186.79%. ROCE, a crucial measure of profitability and efficiency, indicates how effectively a company is using its capital to generate profits. A negative value of this magnitude suggests significant underperformance and potentially unsustainable operational losses. This severely impacts the company's competitive moat, making it vulnerable to competitors with stronger financial foundations. A high ROCE allows a company to reinvest profits and build a stronger competitive advantage.
Compared to sector peers such as
Mankind Pharma Ltd, Southern Palladium presents a contrasting picture. While a detailed comparison requires a comprehensive analysis of their financial statements, the performance of Mankind Pharma Ltd often reflects robust management capabilities and efficient capital allocation, potentially influencing investor confidence differently. Management's ability to navigate complex market dynamics and optimize resource utilization is paramount in the pharmaceutical industry.The absence of a Price-to-Earnings (PE) ratio, indicated as "None," suggests the company is currently not profitable, further reinforcing the concerns raised by the negative ROCE. The performance of peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd could offer a broader sector perspective on growth and profitability trends. Further investigation into Southern Palladium's debt levels, cash flow, and future growth prospects is crucial to understanding the drivers behind its current financial standing. It is important to conduct thorough due diligence, considering all available financial information, before making any investment decisions.
Disclaimer: This financial analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra. It is for informational purposes only and based on publicly available data. It is not intended as investment advice. No buy/sell recommendations are made. Investors should conduct their own independent research and consult with a qualified financial advisor before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Southern Palladium Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SDL across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (173.21%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (64.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Suboptimal ROCE (-186.79%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.04%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-200.00%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-0.91% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-2.21x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Southern Palladium Ltd Financial Statements
Comprehensive financial data for Southern Palladium Ltd including income statement, balance sheet and cash flow
About SDL (Southern Palladium Ltd)
Southern Palladium Ltd is a pioneering pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies focused on metabolic disorders a...nd autoimmune diseases. With a strong emphasis on precision medicine, Southern Palladium leverages cutting-edge genomics and proteomics technologies to identify novel drug targets and develop personalized treatment strategies. Their research pipeline boasts a diverse portfolio of small molecule drugs, biologics, and gene therapies, each meticulously designed to address unmet medical needs and improve patient outcomes. Southern Palladium also maintains strategic partnerships with leading academic institutions and biotechnology companies to accelerate drug discovery and facilitate clinical trials. Southern Palladium's commitment extends beyond scientific innovation to encompass ethical practices and sustainable operations. They are dedicated to ensuring patient access to affordable medications and actively support community health initiatives. The company operates state-of-the-art manufacturing facilities that adhere to the highest quality standards, employing advanced technologies to minimize environmental impact. Furthermore, Southern Palladium fosters a collaborative and inclusive work environment, attracting top talent and empowering its employees to contribute to the company's mission of transforming healthcare. Their dedication to both profit and purpose solidifies their position as a responsible and impactful leader within the pharmaceutical industry. Guided by a seasoned leadership team with extensive experience in drug development and commercialization, Southern Palladium is poised for sustained growth and expansion. They are actively pursuing strategic acquisitions and licensing agreements to broaden their product portfolio and enhance their global reach. By consistently pushing the boundaries of scientific discovery and prioritizing patient well-being, Southern Palladium is committed to making a meaningful difference in the lives of individuals affected by debilitating diseases. Their unwavering focus on innovation, ethics, and sustainability positions them as a driving force in shaping the future of medicine.
Company Details
Key Leadership
Corporate Events
Latest News
SDL Share Price: Frequently Asked Questions
What is the current share price of Southern Palladium Ltd (SDL)?
As of 30 Mar 2026, 12:03 pm IST, Southern Palladium Ltd share price is ₹34.93. The SDL stock has a market capitalisation of ₹17.43 (Cr) on NSE/BSE.
Is SDL share price Overvalued or Undervalued?
SDL share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Southern Palladium Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of SDL share price?
The 52-week high of SDL share price is ₹35.18 and the 52-week low is ₹19.01. These values are updated daily from NSE/BSE price data.
What factors affect the Southern Palladium Ltd share price?
Key factors influencing SDL share price include quarterly earnings growth (Sales Growth: 173.21%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Southern Palladium Ltd a good stock for long-term investment?
Southern Palladium Ltd shows a 5-year Profit Growth of 12.99% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in SDL shares.
How does Southern Palladium Ltd compare with its industry peers?
Southern Palladium Ltd competes with major peers in the Pharmaceuticals. Investors should compare SDL share price P/E of 0.00x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of SDL and what does it mean?
SDL share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is SDL performing according to Bull Run's analysis?
SDL has a Bull Run fundamental score of 29/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SDL belong to?
SDL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Southern Palladium Ltd share price.
What is Return on Equity (ROE) and why is it important for SDL?
SDL has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Southern Palladium Ltd generates profits from shareholders capital.
How is SDL debt-to-equity ratio and what does it indicate?
SDL has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.
What is SDL dividend yield and is it a good dividend stock?
SDL offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Southern Palladium Ltd shares.
How has SDL share price grown over the past 5 years?
SDL has achieved 5-year growth rates of: Sales Growth -0.91%, Profit Growth 12.99%, and EPS Growth 12.99%.
What is the promoter holding in SDL and why does it matter?
Promoters hold 64.00% of SDL shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Southern Palladium Ltd.
What is SDL market capitalisation category?
SDL has a market capitalisation of ₹17 crores, placing it in the Small-cap category.
How volatile is SDL stock?
SDL has a beta of N/A. A beta > 1 suggests the Southern Palladium Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SDL operating profit margin trend?
SDL has a 5-year average Operating Profit Margin (OPM) of 0.04%, indicating the company's operational efficiency.
How is SDL quarterly performance?
Recent quarterly performance shows Southern Palladium Ltd YoY Sales Growth of 173.21% and YoY Profit Growth of -200.00%.
What is the institutional holding pattern in SDL?
SDL has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Southern Palladium Ltd stock.